Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Inflammatory Bowel Diseases 2Crohn Disease 2

Interventions

Infliximab 5Certolizumab Pegol 5Adalimumab 3Nivolumab 2MEDI2070 2Educational Status 2CT-P13 2vedolizumab 1secukinumab 1golimumab 1cabozantinib 1Vitamin E 1Vaccines 1Ustekinumab 1Sutures 1Surveys and Questionnaires 1Surgical Instruments 1Standard of Care 1Specimen Handling 1Soybean Oil 1Saline Solution 1Ringer's Lactate 1Proctocolectomy, Restorative 1Practice Guidelines as Topic 1Pneumococcal Vaccines 1Platinum Compounds 1Photoplethysmography 1Phlebotomy 1Papillomavirus Vaccines 1Methoxsalen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Crohn Disease × MEDI2070 × Clear all
NCT01714726 2021-05-26

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

AstraZeneca

Phase 2 Completed
121 enrolled 22 charts

Crohn Disease, Inflammatory Bowel Diseases

NCT02574637 2021-05-26

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease

AstraZeneca

Phase 2 Terminated
29 enrolled 25 charts

Crohn Disease, Inflammatory Bowel Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡